194 related articles for article (PubMed ID: 16198981)
1. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.
Overgaard J; Eriksen JG; Nordsmark M; Alsner J; Horsman MR;
Lancet Oncol; 2005 Oct; 6(10):757-64. PubMed ID: 16198981
[TBL] [Abstract][Full Text] [Related]
2. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
[TBL] [Abstract][Full Text] [Related]
3. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J;
Radiother Oncol; 2010 Jan; 94(1):30-5. PubMed ID: 19910068
[TBL] [Abstract][Full Text] [Related]
4. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
Nordsmark M; Eriksen JG; Gebski V; Alsner J; Horsman MR; Overgaard J
Radiother Oncol; 2007 Jun; 83(3):389-97. PubMed ID: 17499868
[TBL] [Abstract][Full Text] [Related]
5. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
Eriksen JG; Overgaard J;
Radiother Oncol; 2007 Jun; 83(3):383-8. PubMed ID: 17543403
[TBL] [Abstract][Full Text] [Related]
6. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials.
Hoff CM; Lassen P; Eriksen JG; Hansen HS; Specht L; Overgaard M; Grau C; Johansen J; Bentzen J; Andersen L; Evensen JF; Overgaard J
Acta Oncol; 2011 Oct; 50(7):1006-14. PubMed ID: 21790306
[TBL] [Abstract][Full Text] [Related]
7. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.
Overgaard J; Hansen HS; Specht L; Overgaard M; Grau C; Andersen E; Bentzen J; Bastholt L; Hansen O; Johansen J; Andersen L; Evensen JF
Lancet; 2003 Sep; 362(9388):933-40. PubMed ID: 14511925
[TBL] [Abstract][Full Text] [Related]
8. Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial.
Hassan Metwally MA; Jansen JA; Overgaard J
Clin Oncol (R Coll Radiol); 2015 Mar; 27(3):168-75. PubMed ID: 25530485
[TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.
Overgaard J; Hansen HS; Overgaard M; Bastholt L; Berthelsen A; Specht L; Lindeløv B; Jørgensen K
Radiother Oncol; 1998 Feb; 46(2):135-46. PubMed ID: 9510041
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells.
Sørensen BS; Busk M; Olthof N; Speel EJ; Horsman MR; Alsner J; Overgaard J
Radiother Oncol; 2013 Sep; 108(3):500-5. PubMed ID: 23953409
[TBL] [Abstract][Full Text] [Related]
11. Treatment of head and neck cancer with CHART and nimorazole: phase II study.
Henk JM; Bishop K; Shepherd SF
Radiother Oncol; 2003 Jan; 66(1):65-70. PubMed ID: 12559522
[TBL] [Abstract][Full Text] [Related]
12. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer.
Hui EP; Sung FL; Yu BK; Wong CS; Ma BB; Lin X; Chan A; Wong WL; Chan AT
Clin Cancer Res; 2008 Nov; 14(21):7080-7. PubMed ID: 18981006
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).
Thomson DJ; Slevin NJ; Baines H; Betts G; Bolton S; Evans M; Garcez K; Irlam J; Lee L; Melillo N; Mistry H; More E; Nutting C; Price JM; Schipani S; Sen M; Yang H; West CM;
Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):771-782. PubMed ID: 38072326
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer.
Cottrill CP; Bishop K; Walton MI; Henk JM
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):807-10. PubMed ID: 9845101
[TBL] [Abstract][Full Text] [Related]
15. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
[TBL] [Abstract][Full Text] [Related]
16. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.
Le QT; Sutphin PD; Raychaudhuri S; Yu SC; Terris DJ; Lin HS; Lum B; Pinto HA; Koong AC; Giaccia AJ
Clin Cancer Res; 2003 Jan; 9(1):59-67. PubMed ID: 12538452
[TBL] [Abstract][Full Text] [Related]
17. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J
J Clin Oncol; 2009 Apr; 27(12):1992-8. PubMed ID: 19289615
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.
Henke M; Laszig R; Rübe C; Schäfer U; Haase KD; Schilcher B; Mose S; Beer KT; Burger U; Dougherty C; Frommhold H
Lancet; 2003 Oct; 362(9392):1255-60. PubMed ID: 14575968
[TBL] [Abstract][Full Text] [Related]
19. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of supplemental beta-carotene to prevent second head and neck cancer.
Mayne ST; Cartmel B; Baum M; Shor-Posner G; Fallon BG; Briskin K; Bean J; Zheng T; Cooper D; Friedman C; Goodwin WJ
Cancer Res; 2001 Feb; 61(4):1457-63. PubMed ID: 11245451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
